Cargando…

The Anti-Parkinsonism Effects of K(ATP) Channel Blockade in the 6-Hydroxydopamine-Induced Animal Model: The Role of Oxidative Stress

INTRODUCTION: Studies suggest that ATP-sensitive potassium (K(ATP)) channels are a potential pharmacotherapeutic target for neuroprotection in neurodegenerative diseases. The current study aimed at evaluating the effect of pretreatment with glibenclamide (Glib) and B vitamins supplement on the sever...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piri, Hossein, Haghdoost-Yazdi, Hashem, Fraidouni, Negin, Dargahi, Tahereh, Yaghoubidoust, Mohamadhosein, Azadmehr, Abbas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iranian Neuroscience Society 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535324/ https://www.ncbi.nlm.nih.gov/pubmed/28781726 http://dx.doi.org/10.18869/nirp.bcn.8.3.183

Ejemplares similares

Blockade of fast A-type and TEA-sensitive potassium channels provide an antiparkinsonian effect in a 6-OHDA animal model
por: Haghdoost-Yazdi, Hashem, et al.
Publicado: (2017)

Evaluation of the Association Between Serum Levels of Testosterone and Prolactin With 6- Hydroxydopamine-Induced Parkinsonism in Male Rats
por: Razaghi, Roghaieh, et al.
Publicado: (2021)

Amphiregulin blockade decreases the levodopa‐induced dyskinesia in a 6‐hydroxydopamine Parkinson's disease mouse model
por: Kambey, Piniel Alphayo, et al.
Publicado: (2023)

Mitochondrial Dynamics and Mitophagy in the 6-Hydroxydopamine Preclinical Model of Parkinson's Disease
por: Galindo, Maria F., et al.
Publicado: (2012)

Parkinson’s Disease and the Heart: Studying Cardiac Metabolism in the 6-Hydroxydopamine Model
por: Silva da Fonsêca, Victor, et al.
Publicado: (2023)

Lesioning of the Striatum Reverses Motor Asymmetry in the 6-Hydroxydopamine Rodent Model of Parkinsonism
por: Friehs, G. M., et al.
Publicado: (1991)

Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson’s Disease
por: Pišlar, Anja, et al.
Publicado: (2018)

Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease
por: Ghalami, Jamileh, et al.
Publicado: (2021)

Cardiac and Autonomic Dysfunctions Assessed Through Recurrence Quantitative Analysis of Electrocardiogram Signals and an Application to the 6-Hydroxydopamine Parkinson’s Disease Animal Model
por: Shinoda, Lucas, et al.
Publicado: (2021)

Glyburide Regulates UCP1 Expression in Adipocytes Independent of K(ATP) Channel Blockade
por: Qiu, Yan, et al.
Publicado: (2020)

Activin A Protects Midbrain Neurons in the 6-Hydroxydopamine Mouse Model of Parkinson’s Disease
por: Stayte, Sandy, et al.
Publicado: (2015)

Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models
por: Liu, Lan-Xiang, et al.
Publicado: (2018)

Metabolomics and biochemical alterations caused by pleiotrophin in the 6-hydroxydopamine mouse model of Parkinson’s disease
por: Gramage, Esther, et al.
Publicado: (2022)

Intranasal delivery of mitochondria for treatment of Parkinson’s Disease model rats lesioned with 6-hydroxydopamine
por: Chang, Jui-Chih, et al.
Publicado: (2021)

Propolis induces cardiac metabolism changes in 6-hydroxydopamine animal model: A dietary intervention as a potential cardioprotective approach in Parkinson’s disease
por: Goncalves, Valeria C., et al.
Publicado: (2022)

Cognitive-Enhancing Effect of Quercetin in a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine
por: Sriraksa, Napatr, et al.
Publicado: (2012)

Treadmill exercise alleviates short-term memory impairment in 6-hydroxydopamine-induced Parkinson’s rats
por: Cho, Han-Sam, et al.
Publicado: (2013)

Expression of Tgfβ1 and Inflammatory Markers in the 6-hydroxydopamine Mouse Model of Parkinson’s Disease
por: Haas, Stefan Jean-Pierre, et al.
Publicado: (2016)

Impaired Voluntary Wheel Running Behavior in the Unilateral 6-Hydroxydopamine Rat Model of Parkinson's Disease
por: Pan, Qi, et al.
Publicado: (2015)

Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease
por: De Jesús-Cortés, Héctor, et al.
Publicado: (2015)

Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson’s disease
por: Westphal, Robert, et al.
Publicado: (2017)

GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson’s Disease
por: Renko, Juho-Matti, et al.
Publicado: (2020)

Transcriptome profiling of five brain regions in a 6‐hydroxydopamine rat model of Parkinson’s disease
por: Lyu, Ying, et al.
Publicado: (2021)

Changes in the Neuronal Architecture of the Hippocampus in a 6-Hydroxydopamine-Lesioned Rat Model of Parkinson Disease
por: Kim, Bohye, et al.
Publicado: (2022)

Neuroprotective Effect of Pseudoginsenoside-F11 on a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine
por: Wang, Jian Yu, et al.
Publicado: (2013)

Neuroprotective Effect of Quercetin Nanocrystal in a 6-Hydroxydopamine Model of Parkinson Disease: Biochemical and Behavioral Evidence
por: Ghaffari, Fatemeh, et al.
Publicado: (2018)

Neuroprotective Activity of Some Marine Fungal Metabolites in the 6-Hydroxydopamin- and Paraquat-Induced Parkinson’s Disease Models
por: Yurchenko, Ekaterina A., et al.
Publicado: (2018)

Carnosine suppresses neuronal cell death and inflammation induced by 6-hydroxydopamine in an in vitro model of Parkinson's disease
por: Kubota, Maho, et al.
Publicado: (2020)

Lipid Analysis of the 6-Hydroxydopamine-Treated SH-SY5Y Cell Model for Parkinson’s Disease
por: Xicoy, Helena, et al.
Publicado: (2019)

Lipid profiles in the cerebrospinal fluid of rats with 6-hydroxydopamine-induced lesions as a model of Parkinson’s disease
por: Qiu, Jiewen, et al.
Publicado: (2023)

Prosaposin PS18 reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson’s disease
por: Wu, Kuo-Jen, et al.
Publicado: (2023)

The dosage of curcumin to alleviate movement symptoms in a 6-hydroxydopamine-induced Parkinson's disease rat model
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Treatment with a Substance P Receptor Antagonist Is Neuroprotective in the Intrastriatal 6-Hydroxydopamine Model of Early Parkinson's Disease
por: Thornton, Emma, et al.
Publicado: (2012)

Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
por: Shin, Keon Sung, et al.
Publicado: (2015)

Ellagic Acid Protects the Brain Against 6-Hydroxydopamine Induced Neuroinflammation in a Rat Model of Parkinson’s Disease
por: Farbood, Yaghoob, et al.
Publicado: (2015)

Modafinil Improves Catalepsy in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease; Possible Involvement of Dopaminergic Neurotransmission
por: Vajdi-Hokmabad, Reza, et al.
Publicado: (2017)

NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson’s disease
por: Cheng, Li, et al.
Publicado: (2018)

Tetramethylpyrazine Analogue T-006 Exerts Neuroprotective Effects against 6-Hydroxydopamine-Induced Parkinson's Disease In Vitro and In Vivo
por: Zhou, Hefeng, et al.
Publicado: (2019)

Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson’s Disease
por: Teixeira, Fábio G., et al.
Publicado: (2020)

Probiotic Enhancement of Antioxidant Capacity and Alterations of Gut Microbiota Composition in 6-Hydroxydopamin-Induced Parkinson’s Disease Rats
por: Tsao, Shu-Ping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ua76vlg3esj5r7uc6e5ucgcplj